FDA Approves Firdapse for Rare Autoimmune Disorder

Share this content:
FDA Approves Firdapse for Rare Autoimmune Disorder
FDA Approves Firdapse for Rare Autoimmune Disorder

THURSDAY, Nov. 29, 2018 (HealthDay News) -- Firdapse (amifampridine) tablets have been approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton myasthenic syndrome (LEMS).

The drug is the first agency-sanctioned treatment for the autoimmune disease that affects the connections between nerves and muscles. LEMS affects about three people per one million worldwide, the FDA said. The disorder most commonly occurs among people with cancer, such as small cell lung cancer.

The drug's safety and effectiveness were evaluated in clinical studies involving 64 adults. Using a 13-item physician-rated categorical scale assessing muscle weakness and a seven-point scale on which patients rated their overall impression of the effects of the study treatment on their physical well-being, researchers found that those treated with Firdapse benefited more than those who took a placebo, the agency said. The drug's most common side effects included paresthesia, upper respiratory tract infection, abdominal pain, nausea, diarrhea, headache, and elevated liver enzymes. Patients who have a hypersensitivity reaction such as rash, hives, itching, fever, swelling, or trouble breathing should immediately contact their health care provider.

"Patients with LEMS have significant weakness and fatigue that can often cause great difficulties with daily activities," Billy Dunn, M.D., director of the FDA's Division of Neurology Products, said in an agency news release. "There has been a long-standing need for a treatment for this rare disorder."

Firdapse is produced by Catalyst Pharmaceuticals, based in Coral Gables, Florida.

More Information

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Wait Times Have Improved in VA Health Care System

Wait Times Have Improved in VA Health Care ...

Wait times similar to private sector in 2014 but shorter overall and in some specialties in 2017

Medication Treatment for Substance Abuse Up in Facilities

Medication Treatment for Substance Abuse Up in Facilities

2007 to 2016 saw increase in use of medication treatment, reaching 36.1 percent in 2016

Mindfulness, Stress Linked to Menopausal Symptoms

Mindfulness, Stress Linked to Menopausal Symptoms

Link between mindfulness and symptoms more robust in women experiencing higher stress

is free, fast, and customized just for you!




Already a member?

Sign In Now »